{
  "image_filename": "table_p1_mrg_det_0_017.png",
  "image_path": "FlublokPI/extracted/figures/table_p1_mrg_det_0_017.png",
  "image_type": "Table",
  "page_number": 1,
  "block_id": "mrg_det_0_017",
  "claim_id": "claim_003",
  "claim": "Recombinant technology leads to a broader immune response that may provide cross-protection, even in a mismatch season.",
  "supports_claim": false,
  "explanation": "Page 1 of the full prescribing information showing a table of contents with sections for indications, dosage, contraindications, warnings, adverse reactions, clinical pharmacology, nonclinical toxicology, clinical studies (14.1 efficacy against laboratory-confirmed influenza), and other standard prescribing sections. The image only shows the section headings of prescribing information and no data or statements regarding recombinant technology, broader immune responses, or cross-protection; it does not support the claim. Note: The image quality limits visibility to only section titles; no study data or narrative content is shown.",
  "model_used": "o4-mini",
  "detailed_analysis": {
    "supports_claim": false,
    "image_description": "Page 1 of the full prescribing information showing a table of contents with sections for indications, dosage, contraindications, warnings, adverse reactions, clinical pharmacology, nonclinical toxicology, clinical studies (14.1 efficacy against laboratory-confirmed influenza), and other standard prescribing sections.",
    "evidence_found": null,
    "reasoning": "The image only shows the section headings of prescribing information and no data or statements regarding recombinant technology, broader immune responses, or cross-protection; it does not support the claim.",
    "confidence_notes": "The image quality limits visibility to only section titles; no study data or narrative content is shown."
  }
}